ACTG 175: Anti-HIV Therapy Lowers Risk of AIDS, Death in Patients with Intermediate-Stage HIV Disease. The National Institute of Allergy and Infectious Diseases (NIAID) reports that anti-HIV treatment of individuals with intermediate-stage HIV disease can lower their risk of developing AIDS and, in certain patients, can reduce the risk of death. In a study of 2,500 HIV-infected volunteers, the drug didanosine (ddI), the combination of ddI plus zidovudine (AZT), and the combination of zalcitabine (ddC) plus AZT were each superior to the widely used first-line therapy, AZT alone, in preventing one or more serious consequences of HIV infection. Click here for the full text of the press release and NIAID's questions and answers on ACTG 175.
A new Glossary of HIV/AIDS-Related Terms has been produced by the HIV/AIDS Treatment Information Service. The 110-page glossary defines words that are commonly used to describe the development and diagnosis of HIV disease, the treatment of HIV infection and AIDS, and the medical management of related conditions. Take a look and download the text of the glossary in the CDC NAC gopher, e-mail your order for a free printed copy to firstname.lastname@example.org, or place your order by phone, 1-800-458-5231.
Guidelines for the prevention of 17 opportunistic infections in persons with HIV disease were recently issued by the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA). These guidelines are intended both for primary health care providers and for specialists who care for HIV-infected adults, adolescents, and children. They can also provide useful information for persons living with HIV disease.
The full text of the guidelines was published in a supplement to Clinical Infectious Diseases (August 1995). The July 14, 1995, issue of CDC's Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports series is an excerpt from the Clinical Infectious Diseases supplement. Read and download the MMWR from the CDC NAC gopher, e-mail your order for the MMWR or the Clinical Infectious Diseases Supplement to email@example.com or place your order by phone, 1-800-458-5231.
Current Information About Experimental and Approved Treatments for HIV/AIDS briefly describes the experimental treatments that are making headlines and have generated the most questions from callers to the AIDS Clinical Trials Information Service. The treatments listed use drugs and therapies that are currently being tested; information is current as of August 24, 1995. The chart at the end of the brief contains a list of drugs currently approved by the Food and Drug Administration for HIV infection and related conditions.